WallStreetZenWallStreetZen

NASDAQ: CORT
Corcept Therapeutics Inc Stock

$33.24-0.10 (-0.3%)
Updated Jul 17, 2024
CORT Price
$33.24
Fair Value Price
$84.02
Market Cap
$3.46B
52 Week Low
$20.84
52 Week High
$35.22
P/E
28.9x
P/B
6.32x
P/S
4.95x
PEG
1.32x
Dividend Yield
N/A
Revenue
$523.53M
Earnings
$117.19M
Gross Margin
98.5%
Operating Margin
23.13%
Profit Margin
22.4%
Debt to Equity
0.2
Operating Cash Flow
$125M
Beta
0.73
Next Earnings
Jul 31, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CORT Overview

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CORT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CORT ($33.24) is undervalued by 60.44% relative to our estimate of its Fair Value price of $84.02 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CORT ($33.24) is significantly undervalued by 60.44% relative to our estimate of its Fair Value price of $84.02 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CORT ($33.24) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CORT due diligence checks available for Premium users.

Be the first to know about important CORT news, forecast changes, insider trades & much more!

CORT News

Valuation

CORT fair value

Fair Value of CORT stock based on Discounted Cash Flow (DCF)
Price
$33.24
Fair Value
$84.02
Undervalued by
60.44%
CORT ($33.24) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CORT ($33.24) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CORT ($33.24) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CORT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
28.9x
Industry
-21.17x
Market
30.24x
CORT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CORT is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

CORT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
6.32x
Industry
6.35x
CORT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CORT price to earnings growth (PEG)

For valuing profitable companies with growth potential
CORT is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

CORT's financial health

Profit margin

Revenue
$146.8M
Net Income
$27.5M
Profit Margin
18.7%
CORT's Earnings (EBIT) of $121.09M... subscribe to Premium to read more.
Interest Coverage Financials
CORT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$655.9M
Liabilities
$108.1M
Debt to equity
0.2
CORT's short-term assets ($503.37M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CORT's short-term assets ($503.37M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CORT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CORT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$23.8M
Investing
-$9.0M
Financing
-$543.0k
CORT's operating cash flow ($124.84M)... subscribe to Premium to read more.
Debt Coverage Financials

CORT vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CORT$3.46B-0.30%28.90x6.32x
ARWR$3.48B-5.15%-6.61x7.19x
ACLX$3.50B-0.62%-63.60x7.06x
TGTX$3.41B-1.95%76.14x21.31x
MRUS$3.32B-3.89%-20.42x9.50x

Corcept Therapeutics Stock FAQ

What is Corcept Therapeutics's quote symbol?

(NASDAQ: CORT) Corcept Therapeutics trades on the NASDAQ under the ticker symbol CORT. Corcept Therapeutics stock quotes can also be displayed as NASDAQ: CORT.

If you're new to stock investing, here's how to buy Corcept Therapeutics stock.

What is the 52 week high and low for Corcept Therapeutics (NASDAQ: CORT)?

(NASDAQ: CORT) Corcept Therapeutics's 52-week high was $35.22, and its 52-week low was $20.84. It is currently -5.62% from its 52-week high and 59.5% from its 52-week low.

How much is Corcept Therapeutics stock worth today?

(NASDAQ: CORT) Corcept Therapeutics currently has 104,112,088 outstanding shares. With Corcept Therapeutics stock trading at $33.24 per share, the total value of Corcept Therapeutics stock (market capitalization) is $3.46B.

Corcept Therapeutics stock was originally listed at a price of $12.23 in Apr 14, 2004. If you had invested in Corcept Therapeutics stock at $12.23, your return over the last 20 years would have been 171.79%, for an annualized return of 5.13% (not including any dividends or dividend reinvestments).

How much is Corcept Therapeutics's stock price per share?

(NASDAQ: CORT) Corcept Therapeutics stock price per share is $33.24 today (as of Jul 17, 2024).

What is Corcept Therapeutics's Market Cap?

(NASDAQ: CORT) Corcept Therapeutics's market cap is $3.46B, as of Jul 18, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Corcept Therapeutics's market cap is calculated by multiplying CORT's current stock price of $33.24 by CORT's total outstanding shares of 104,112,088.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.